Last reviewed · How we verify
NCT03750669
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Phase 3 trial testing AG regimen in Pancreatic Adenocarcinoma Resectable in 324 participants. Completed in 1 March 2025.
1 November 2024
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 324 |
| Start date | 20 October 2018 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- AG regimen — full drug profile →
- mFolfirinox
Conditions studied
- Pancreatic Adenocarcinoma Resectable — all drugs for Pancreatic Adenocarcinoma Resectable →
- Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Adults 18 to 75, any sex, with Pancreatic Adenocarcinoma Resectable or Neoadjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen. Studies have shown that sequential chemotherapeutic regimen can effectively delay the drug resistance and improve the effect of chemotherapy. Here investigators intend to assess the effect of sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox as neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
Seufferlein T, Ettrich TJ. · · 2019 · cited 35× · PMID 30976724 · DOI 10.21037/tgh.2019.03.05 -
Immunological combination treatment holds the key to improving survival in pancreatic cancer.
Sodergren MH, Mangal N, Wasan H, Sadanandam A, et al · · 2020 · cited 20× · PMID 32748119 · DOI 10.1007/s00432-020-03332-5 -
Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review.
Endo Y, Kitago M, Kitagawa Y. · · 2024 · cited 10× · PMID 38730584 · DOI 10.3390/cancers16091632 -
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.
Bai X, Li X, Chen Y, Qiao G, et al · · 2025 · cited 5× · PMID 41072417 · DOI 10.1016/j.ccell.2025.09.009 -
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, et al · · 2022 · cited 5× · PMID 35599791 · DOI 10.3389/fsurg.2022.866173 -
Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis.
Zhang HQ, Li J, Tan CL, Chen YH, et al · · 2022 · cited 4× · PMID 36310705 · DOI 10.4251/wjgo.v14.i10.1903 -
Neoadjuvant treatment of localized pancreatic adenocarcinoma.
Leal AD, Messersmith WA, Lieu CH. · · 2021 · cited 1× · PMID 34790407 · DOI 10.21037/jgo-20-250
Verify or expand the search:
- PubMed search for NCT03750669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AG regimen
Trials testing the same drug.
- NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting
- NCT07312422 — LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study · Phase 1, PHASE2 · recruiting
- NCT06938503 — AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
Other recruiting trials for Pancreatic Adenocarcinoma Resectable
Currently open trials in the same condition.
- NCT06966440 — Adjuvant Pancreatic Therapy Guided by MRD · NA · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03750669 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing